Harbor Capital Advisors Inc. lowered its position in Piper Sandler Companies (NYSE:PIPR – Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a

Piper Sandler Companies (NYSE:PIPR – Get Free Report)’s stock price was down 1.4% during trading on Tuesday . The stock traded as low as $293.09 and last traded at $297.24. Approximately 150,516 shares changed hands during mid-day trading,

Fintel reports that on January 6, 2025, Goldman Sachs downgraded their outlook for Piper Sandler Companies (NYSE:PIPR) from Buy to Neutral. Analyst Price Forecast Suggests 25.14% Upside As of December 23,

CF Industries Holdings, Inc. (CF) stock saw a modest uptick, ending the day at $96.37 which represents a slight increase of $1.38 or 1.45% from the prior close of $94.99. The stock opened at $95.1 and touched a low of $94.

View Piper Sandler Companies (PIPR) current and estimated P/E ratio data provided by Seeking Alpha.

Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of John Kerins as a managing director to the healthcare investment banking team. Kerins will ...

LONDON, January 06, 2025--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Paul Leece, Jeremi Martin and Daniel Allmomen to its energy ...